MENU
+Compare
MREO
Stock ticker: NASDAQ
AS OF
Dec 12 closing price
Price
$2.17
Change
-$0.08 (-3.56%)
Capitalization
345.32M

MREO Mereo BioPharma Group plc Forecast, Technical & Fundamental Analysis

Mereo BioPharma Group PLC is a United Kingdom (U... Show more

MREO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for MREO with price predictions
Dec 11, 2025

Aroon Indicator for MREO shows an upward move is likely

MREO's Aroon Indicator triggered a bullish signal on December 11, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 163 similar instances where the Aroon Indicator showed a similar pattern. In of the 163 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 03, 2025. You may want to consider a long position or call options on MREO as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MREO just turned positive on November 25, 2025. Looking at past instances where MREO's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

MREO moved above its 50-day moving average on December 03, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MREO crossed bullishly above the 50-day moving average on December 09, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MREO advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MREO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MREO broke above its upper Bollinger Band on December 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MREO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.413) is normal, around the industry mean (28.362). P/E Ratio (0.000) is within average values for comparable stocks, (51.986). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.836). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (666.667) is also within normal values, averaging (336.196).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MREO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
MREO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

MREO is expected to report earnings to fall 114.00% to 0 cents per share on April 01

Mereo BioPharma Group plc MREO Stock Earnings Reports
Q4'25
Est.
$0.00
Q3'25
Missed
by $0.02
Q2'25
Est.
$-0.02
Q1'25
Missed
by $0.03
Q4'24
Est.
$-0.01
The last earnings report on November 10 showed earnings per share of 0 cents, missing the estimate of 1 cents. With 2.21M shares outstanding, the current market capitalization sits at 345.32M.
A.I. Advisor
published General Information

General Information

a company, which engages in therapeutics that aim to improve outcomes for patients with osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism in obese men, and acute exacerbations of chronic obstructive pulmonary disease

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
One Cavendish Place
Phone
+44 3330237300
Employees
33
Web
https://www.mereobiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CIHKY32.960.54
+1.67%
China Merchants Bank Co., Ltd.
CATWF0.07N/A
N/A
China Tontine Wines Group Ltd.
ATSKF0.88N/A
N/A
Allied Telesis Holdings KK
SUGBY80.02N/A
N/A
Suruga Bank Ltd.
MAKSY8.66-0.07
-0.80%
Marks & Spencer Group Plc

MREO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MREO has been closely correlated with RARE. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if MREO jumps, then RARE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
-2.60%
RARE - MREO
69%
Closely correlated
+0.56%
TRDA - MREO
43%
Loosely correlated
+2.08%
SYRE - MREO
39%
Loosely correlated
-0.87%
NRIX - MREO
39%
Loosely correlated
-2.75%
XNCR - MREO
38%
Loosely correlated
-0.58%
More

Groups containing MREO

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
-2.60%
MREO
(2 stocks)
74%
Closely correlated
-1.64%